| Value | ₹0.26 Cr |
|---|
BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹788.00
- Market cap
- ₹15,489 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 22.3×Sector 46.5×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.23 Cr
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
- Value
- ₹0.23 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
Alembic Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Alembic Pharmaceuticals Debt & Borrowing
Alembic Pharmaceuticals submitted a certificate confirming the utilization of proceeds from Commercial Papers for the quarter ended September 30, 2026, as required by SEBI regulations.
Other merger & restructuring announcements
All →Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr
Vraj Iron & Steel Merger & Restructuring Worth ₹4.55 Cr
Vraj Iron and Steel transferred 396,000 MVK Industries shares to promoter Gopal Sponge for Rs 4.55 Crore. The sale was completed on October 28, 2026.
- Value
- ₹4.55 Cr
KPIT Technologies Merger & Restructuring Worth ₹19.2 Cr
KPIT Technologies will incorporate a new Vietnam subsidiary for mobility engineering, with 100% control. The company commits USD 2 million (about Rs 19.20 Crore) in cash.
- Value
- ₹19.20 Cr
Megatherm Induction Merger & Restructuring
Megatherm Induction incorporated Sictech India Private Limited, a joint venture with Smart Induction Converter Technologies, holding 49%. The JV will manufacture and commercialise advanced Induction Converter Modules.
Eco Recycling Merger & Restructuring Worth ₹0.05 Cr
Eco Recycling incorporated a 50:50 joint venture, ERI India Private Limited, with Electronic Recyclers International. The company subscribed 50,000 shares for ₹0.05 Crore.
- Value
- ₹0.05 Cr